A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
1 report, 1 independent
Updated Aug 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.Sub-event
Seeking FDA clearance for IND application for combination therapies.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Exelixis
American biotechnology company
Nothing else this week.
- FDA
Related events
- Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Experimental therapies require approval from the FDA.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
Coverage
Newest first; wire copies grouped- Insider MonkeyExelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Exelixis, Inc. is one of them. Exelixis, Inc. (NASDAQ